Our research focuses on understanding what causes morbidity from asthma and COPD and how to best prevent or treat these common chronic conditions.
Dr. Mario Castro, MD, MPH, Division Chief of Pulmonary, Critical Care and Sleep Medicine, Vice Chair for Clinical and Translational Research, Director of the Rainbow Clinical and Translational Science Unit (CTSU, Frontiers), leads the AATRU group, which currently has more than 25 ongoing studies, all of which have opportunities for students, residents, felows and junior faculty to perform focused research in an area of interest.
LEARN MORE ABOUT OUR AIRWAY AND ASTHMA TRANSLATIONAL RESEARCH
We are dedicated to advancing treatment and therapies available to individuals with an active COVID-19 infection.
We are the only outpatient COVID-positive research center in the state of Kansas and in the region.
KUMC is also focused on expanding upon research and developing new treatments and testing for individuals that are recovering from COVID-19, are recovered from COVID-19, and have long term post-COVID-19 symptoms (“long haul”).
The University of Kansas Medical Center hosts the largest cystic fibrosis care center in the state of Kansas. Our dedicated team of research professionals is committed to working to advance the treatment of CF through different clinical trials aimed at finding novel and more efficient ways to treat patients with this rare genetic disease.
Dr. Matthias Salathe's laboratory studies airway diseases, from bench to bedside. Our group has an active clinical trials environment involving PI initiated and pharmaceutically sponsored trials and is developing novel anti-inflammatory therapies for cystic fibrosis.
The Interstitial Lung Disease Research Team at the University of Kansas Medical Center is dedicated to advancing treatment, therapeutics, and prognosis for Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, & Sarcoidosis.
We are the only National Center of Excellence for patients with Interstitial Lung Disease in the state of Kansas and one of the few centers located in the Midwest.
Our non-CF Bronchiectasis and Non-Tuberculosis Mycobacterial (NTM) research teams are dedicated to advancing treatment and therapies available to people with these life-altering diseases. For additional information about NCFB and NTM research at KUMC, go the Non-CF Bronchiectasis and NTM homepage.
At the University of Kansas Medical Center, we are dedicated to enhancing a better understanding of the rare disease, primary ciliary dyskinesia (PCD) and finding novel and more efficient ways to treat patients with this life-altering disease.
At the University of Kansas Medical Center, we have a robust clinical and translational science research program with a primary mission of the advancement and treatment of Pulmonary Hypertension. In addition, we are the only designated Pulmonary Hypertension Comprehensive Care Center (PHCCC) in the state of Kansas and the region. We are dedicated to enhancing a better understanding of pulmonary hypertension and finding novel and more efficient ways to treat patients with this life-altering disease.
We are highly active in outcomes research and research into the delivery of evidence-based care.
Specific areas of interest include outcomes of sepsis treatment in rural settings, determinants of outcome in the quarternary medical center, use of electronic early warning systems for sepsis diagnosis, and outcomes in patients with specific conditions, such as hematological malignancies and pulmonary hypertension.
We have also worked with members of the School of Engineering at Kansas State University to develop agent-based models of innate immunity in sepsis.